Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Ipilimumab + Nivolumab + SBRT in Stage IV PDAC
NCT05088889Phase 1Unknown
- Sponsor
- Sheba Medical Center
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sheba Medical Center. Primary endpoints: Objective tumor response rate 1 at 36 months and Objective tumor response rate 2 at 36 months. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05088889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088889.